<DOC>
	<DOC>NCT00242567</DOC>
	<brief_summary>This study aims to determine whether early treatment with zoledronic acid, that is given during the early phase of advanced prostate cancer, will be more efficacious than delayed treatment</brief_summary>
	<brief_title>Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>prostate cancer at least one bone metastasis receiving or about to receive androgen deprivation therapy (ADT) previous ADT failure previous or current treatment with another boneprotecting agent, chemotherapy or targeted therapy abnormal renal function Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>zoledronic acid</keyword>
	<keyword>bone metastases</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>hormone-sensitive</keyword>
</DOC>